Vanda Pharmaceuticals (VNDA) Free Cash Flow (2010 - 2026)

Vanda Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at -$50.4 million in Q1 2026.

• Quarterly Free Cash Flow fell 50.19% year-over-year to -$50.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$127.3 million (down 121.8% YoY) and the FY2025 annual result came in at -$110.4 million, down 579.76% from the prior year.
• Free Cash Flow fell to -$50.4 million in Q1 2026 per VNDA's latest filing, from -$29.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $31.8 million in Q1 2023 and troughed at -$50.4 million in Q1 2026.
• A 5-year average of -$7.8 million and a median of -$4.0 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow jumped 699.6% in 2023, then plunged 1353.42% in 2025.
• Over 5 years, Free Cash Flow stood at $9.2 million in 2022, then plunged by 143.54% to -$4.0 million in 2023, then jumped by 49.03% to -$2.0 million in 2024, then slumped by 1353.42% to -$29.5 million in 2025, then slumped by 70.87% to -$50.4 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$50.4 million, -$29.5 million, and -$31.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.